Research & Development World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE

Horizon Pharma to Acquire Vidara for $660M

By R&D Editors | March 19, 2014

Horizon Pharma Inc. plans to buy the privately held Vidara Therapeutics International Ltd. in a cash-and-stock deal that will add the immune system disorder drug Actimmune to the specialty drugmaker’s product portfolio.
 
Shares of Horizon soared in premarket trading Wednesday after the Deerfield, Ill., company said it will pay about $660 million in a deal that creates an Ireland-based company named Horizon Pharma PLC.
 
Vidara shareholders will receive $200 million in cash and retain about a 26% stake in Horizon Pharma PLC.
 
Horizon Chairman and CEO Timothy P. Walbert will keep those titles with the combined company.
 
Vidara has operations in both Dublin and the United States. It bought Actimmune from InterMune Inc. in 2012 for $55 million. The drug tallied nearly $59 million in sales for Vidara last year.
 
Walbert said in a statement that the addition of Actimmune complements his company’s business model, which focuses on promotions to primary care doctors and specialists. Horizon’s portfolio already includes Vimovo, which is approved as a treatment for symptoms of osteoarthritis and rheumatoid arthritis.
 
The company also said the deal gives it a “tax efficient corporate structure” to support growth and acquisitions.
 
Horizon said the boards of both companies have unanimously approved the acquisition, which is expected to close in the middle of the year.
 
The shares have nearly doubled in value since closing 2013 at $7.62.
 
Date: March 19, 2014
Source: Associated Press

Related Articles Read More >

Probiotics power a bioresorbable battery that can run from 4 to 100+ minutes
2025 R&D layoffs tracker tops 92,000
Health-related innovation in Morocco highlighted by resident inventor patenting activity
ARPA-H funds $29M Ginkgo-led project to reshore pharma supply chains using wheat germ tech
rd newsletter
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest info on technologies, trends, and strategies in Research & Development.
RD 25 Power Index

R&D World Digital Issues

Fall 2024 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R&D magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • Global Funding Forecast

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE